Haemonetics Corporation (HAE) - Total Liabilities
Based on the latest financial reports, Haemonetics Corporation (HAE) has total liabilities worth $1.60 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Haemonetics Corporation to evaluate the company's liquid asset resilience ratio.
Haemonetics Corporation - Total Liabilities Trend (1992–2026)
This chart illustrates how Haemonetics Corporation's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Haemonetics Corporation's balance sheet.
Haemonetics Corporation Competitors by Total Liabilities
The table below lists competitors of Haemonetics Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥4.85 Billion |
|
KANSAI PAINT SPON.ADR/1/2
F:KAP0
|
Germany | €403.87 Billion |
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
USA | $287.74 Million |
|
LandBridge Company LLC
NYSE:LB
|
USA | $554.12 Million |
|
Legend Holdings Corporation
F:1PC
|
Germany | €665.71 Billion |
|
Inari Amertron Bhd
KLSE:0166
|
Malaysia | RM308.02 Million |
|
Harmony Biosciences Holdings
NASDAQ:HRMY
|
USA | $373.84 Million |
|
Qingdao Rural Commercial Bank Corp Class A
SHE:002958
|
China | CN¥472.75 Billion |
Liability Composition Analysis (1992–2026)
This chart breaks down Haemonetics Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Haemonetics Corporation balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Haemonetics Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Haemonetics Corporation (1992–2026)
The table below shows the annual total liabilities of Haemonetics Corporation from 1992 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | $1.50 Billion | -7.85% |
| 2025-03-31 | $1.63 Billion | +31.93% |
| 2024-03-31 | $1.24 Billion | +10.64% |
| 2023-03-31 | $1.12 Billion | +0.59% |
| 2022-03-31 | $1.11 Billion | +2.03% |
| 2021-03-31 | $1.09 Billion | +60.04% |
| 2020-03-31 | $680.00 Million | +12.05% |
| 2019-03-31 | $606.90 Million | +25.16% |
| 2018-03-31 | $484.91 Million | -2.84% |
| 2017-03-31 | $499.10 Million | -16.42% |
| 2016-03-31 | $597.13 Million | -9.11% |
| 2015-03-31 | $657.00 Million | -3.56% |
| 2014-03-31 | $681.23 Million | -1.65% |
| 2013-03-31 | $692.69 Million | +294.57% |
| 2012-03-31 | $175.56 Million | +19.32% |
| 2011-03-31 | $147.13 Million | -8.63% |
| 2010-03-31 | $161.02 Million | +46.64% |
| 2009-03-31 | $109.81 Million | -4.32% |
| 2008-03-31 | $114.76 Million | +23.28% |
| 2007-03-31 | $93.09 Million | -11.26% |
| 2006-03-31 | $104.89 Million | -6.86% |
| 2005-03-31 | $112.62 Million | -11.77% |
| 2004-03-31 | $127.64 Million | -6.12% |
| 2003-03-31 | $135.97 Million | +6.15% |
| 2002-03-31 | $128.10 Million | -1.31% |
| 2001-03-31 | $129.80 Million | -9.02% |
| 2000-03-31 | $142.67 Million | +6.07% |
| 1999-03-31 | $134.50 Million | -5.28% |
| 1998-03-31 | $142.00 Million | +44.60% |
| 1997-03-31 | $98.20 Million | +38.70% |
| 1996-03-31 | $70.80 Million | -18.90% |
| 1995-03-31 | $87.30 Million | +24.89% |
| 1994-03-31 | $69.90 Million | +30.41% |
| 1993-03-31 | $53.60 Million | -1.11% |
| 1992-03-31 | $54.20 Million | -- |
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information tech… Read more